Rajni Agarwal-Hashmi
Academic Appointments
- Associate Professor - Med Center Line, Pediatrics - Stem Cell Transplantation
Key Documents
Contact Information
-
Clinical Offices
Pediatric Stem Cell Transplantation 725 Welch Rd Palo Alto, CA 94304 Tel Work (650) 725-9250 Fax (650) 724-1164Practices at Stanford Hospital and Clinics and Lucile Packard Children's Hospital
- Academic Offices
Personal Information EmailAlternate Contact KathyNakashima Administrator Email Tel Work (650) 725-9250Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Blood and Marrow Transplantation, Pediatric
- Hematology/Oncology/Stem Cell Transplant, Pediatric
- Pediatric Hematology-Oncology
Administrative Appointments
- Section chief, Pediatric Stem Cell Transplantation (2010 - present)
- Associate chief, Pediaric hematology/oncology/stem cell transplantation (2010 - present)
- Clinical Director, Pediatric Stem Cell Transplant (2008 - present)
Honors and Awards
- President's award, Best Woman Candidate in India in Medical School Examinations (1979)
Professional Education
| Residency: | M.G.M Medical College, India (1983) |
| Internship: | M.G.M Medical College, India (1981) |
| Medical Education: | M.G.M Medical College, India (1983) |
| Residency: | Children's Hospital Medical Center, OH USA (1995) |
| Board Certification: | General Pediatrics, American Board of Pediatrics (1996) |
| MD: | Indore University, Pediatrics (1983) |
Community and International Work
Scientific Focus
Current Research Interests
I trained extensively in India as a pediatric Hematologist-Oncologist.Due to a strong interest in pursuing translational research in the field I chose to come to USA.During my stay at children's hospital medical center (CHMC) in Cincinnati, Ohio I developed a strong interest in the field of stem cell biology and transplantation.My experience in this field also included extensive training and expertise obtained at the hospital for sick children,Toronto,Canada and National institutes of health(NIH),USA. At the hospital for sick children I learned and developed stem cell assays and invivo models of human hematopoiesis that were critical in understanding of stem cell biology and its clinical applications. At the NIH I spent Two years with Drs. Nienhuis and Cynthia Dunbar and developed gene transfer assays in Hematopoietic cells. At the NIH I also worked on developing the mammalian models for in vivo gene tranfer in hematopoietic cells.During this time we also published our work on chronic myeloid leukemia addressing the role of interaction of stromal cells with hematopoietic cells in the bone marrow.This publication defined conditions to favor the growth of benign hematopoietic cells in patients with chronic myeloid leukemia.
At CHMC,Cincinnati,I established the stem cell biology laboratory to furthur investigate the field of Hematopoietic stem cells specifically involving the umbilical cord blood.I started the clinical Umbilical cord blood transplant program at CHMC.Through my research efforts we were able to develop a sterile system for collection and use of cord blood cells. This endeavor later contributed in establishing methods to collect and store cord blood for clinical use.In the laboratory we were able to set up the assays to identify and collect highly purified hematopoietic cells from the cord blood. The engraftment and expansion potential of the cord blood derived hematopoietic cells was studied in the immune deficient mice.Also these models were then used to develop assays for gene tranfer in Fanconi Anemia.Currently, at Stanford my focus is to develop clinical research protocols to reduce toxicity from high doses of chemotherapy and radiation therapy,graft manipulation to reduce complications from graft vs. host disease and study late complications of transplant.
Thoughout my academic career,I have maintained my interest and committment in providing not only excellent patient care but to provide basic research data which can be utilized to improve patient care at the end.
Clinical Trials
- Recruiting Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
- Not Recruiting The Adv Halt Trial
- Recruiting Long Term Effects On Recipients of Hematopoietic Stem Cell Transplantation
- Not Recruiting Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT
- Not Recruiting Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
Publications
- High-dose chemotherapy followed by stem cell rescue for high-risk germ cell tumors: the Stanford experience. Bone Marrow Transplant. 2009; (7): 547-52
- Nontuberculous mycobacteria infections in immunocompromised patients: single institution experience. J Pediatr Hematol Oncol. 2009; (8): 556-60
- Pathological evidence of Wolman's disease following hematopoietic stem cell transplantation despite correction of lysosomal acid lipase activity. Bone Marrow Transplant. 2009; (7): 449-50
- Hematopoietic stem cell transplant for pediatric acute promyelocytic leukemia. Biol Blood Marrow Transplant. 2008; (7): 824-30
- Safety of hematopoietic stem cell transplantation in children less than three years of age. Pediatr Hematol Oncol. 2008; (8): 705-22
- Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood. 2006; (5): 1485-91
Help